PCSA - Processa Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Processa Pharmaceuticals, Inc.

7380 Coca Cola Drive
Suite 106
Hanover, MD 21076
United States

Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Dr. David YoungCo- Founder, Chairman & CEON/AN/A1953
Mr. Patrick LinCo-Founder, Chief Bus. & Strategy Officer and Director44.48kN/A1965
Dr. Sian E. BigoraCo-Founder & Chief Devel. Officer50.75kN/A1960
Ms. Wendy GuyCo-Founder & Chief Admin. Officer87.5kN/A1964
Mr. James H. StankerChief Financial Officer116.67kN/A1958
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of drug products for the unmet medical needs. Its lead product candidate is PCS-499, an oral tablet that is in Phase IIa clinical trial for the treatment of necrobiosis lipoidica, an idiopathic disease of the dermis. The company was formerly known as Heatwurx, Inc. and changed its name to Processa Pharmaceuticals, Inc. in October 2017. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Corporate Governance

Processa Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.